Rgenta Therapeutics
Cambridge, US · Founded 2019 · Delaware corporation · 32 employees on LinkedIn · 14 known investors
Find your way into Rgenta Therapeutics
673 people in our graph share verified history with the Rgenta Therapeutics team — schools, employers, funds. One of them is your warm intro.
Vinnie Lauriaunlockedknows Zhiping Weng · together at Boston University (overlapped)
×5knows the team · via Boston University
knows the team · via The University of Texas at Dallas
×4knows the team · via Southern Methodist University
knows the team · via AbbVie
Rgenta develops orally available small molecule therapies that target RNA to address diseases previously considered undruggable, with programs in oncology (targeting proteins such as MYB in solid tumors and hematologic cancers) and central nervous system repeat expansion disorders like Huntington's disease. It operates in the RNA-targeted drug development space.
Founders & leadership
Rgenta Therapeutics was founded in 2019 by Travis Wager, Hualin Simon Xi, Zhiping Weng, and Simon Xi.
TW
Travis WagerinCo-Founder, President and CSOHe brings 25 years of leadership experience in neuroscience, rare disease, and oncology research and drug discovery, with expertise in brain-penetrant small molecule design.
HS
Hualin Simon XiCo-founder
ZW
Zhiping WenginCo-Founder and Scientific AdvisorDr. Zhiping Weng holds the Li Weibo Chair in Biomedical Research at the University of Massachusetts Medical School and directs its Program in Bioinformatics and Integrative Biology. She co-founded Rgenta Therapeutics in 2018 alongside Travis Wager and Simon Hualin Xi, and her research focuses on genomics, epigenomics, and transcriptomics using computational methods to study gene regulation and protein interactions.
SX
Simon XiinCo-founder and CEOSimon Xi has over 20 years of experience in pharmaceutical drug discovery, with expertise in CNS, rare diseases, and oncology, and has led research programs at major pharmaceutical companies. He is co-founder and CEO of Rgenta Therapeutics, which develops orally available small molecule therapies targeting RNA for oncology and neurological disorders, and serves as a principal investigator on NIH-funded genomics consortia and adjunct faculty at Brandeis University.
JW
Jackie WallingCMO
DR
Debasish RoychowdhuryNamed on SEC filing
SL
Sun LinghaoNamed on SEC filing
Board
JL
Judith LiBoard director
MH
Investors · 14
Delos CapitalCambridge
Vivo CapitalPalo Alto · $10M – $50M
AMR Action FundreportedBostonvia Martin Heidecker · board
Boehringer Ingelheim Venture FundreportedIngelheim am Rhein · $16.2M
Korea Investment PartnersreportedSeoul · $973K – $50M
Lilly Asia VenturesreportedHong Kongvia Hongbo Lu · board
Matrix Capital ManagementreportedPortsmouth
Matrix Partners ChinareportedBeijing · $1.6M – $113M
Also in the syndicate · 6
AZ-CICC Healthcare Investment FundleadBIVFleadKaitaiKorean Investment PartnersLilly Asia VentureMatrix Capitalslead
Funding
SEC filings, press & company announcements$88.9M disclosed across 4 rounds · 2020–2022
- $52MSeries ANov 2022 · 3 sources
AZ-CICC Healthcare Investment Fund (lead), Boehringer Ingelheim Venture Fund, Delos Capital, Korean Investment Partners, Lilly Asia Venture, Matrix Partners China, Vivo Capital
Source ↗ - $18Mseed extension roundMay 2021 · 2 sources
BIVF (lead), Matrix Capital (lead), Matrix Capitals (lead), Kaitai, Lilly Asia Venture, Vivo Capital
Source ↗
▶$8.9MraisedFeb 2022 · 6 investors · OtherRule 506(b)
▶$8.9MraisedFeb 2022 · 6 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Judith LiDirector
- Sun LinghaoDirector
- Hualin Simon XiExecutive Officer, Director
- Fei ShenDirector
- Debasish RoychowdhuryDirector
- Hongbo LuDirector
- Travis WagerExecutive Officer
- Zhiping WengDirector
- Offering amount
- $8.9M
- Amount sold
- $8.9M
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$10MraisedMar 2021 · 6 investors · OtherRule 506(b)
▶$10MraisedMar 2021 · 6 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Judith LiDirector
- Hongbo LuDirector
- Debasish RoychowdhuryDirector
- Travis WagerExecutive Officer
- Sun LinghaoDirector
- Hualin Simon XiExecutive Officer, Director
- Zhiping WengDirector
- Martin HeideckerDirector
- Offering amount
- $38M
- Amount sold
- $10M
- First sale
- Jan 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 7
by search overlap
Orna22 shared keywordsOrna Therapeutics develops RNA and lipid nanoparticle (LNP) based therapies for treating diseases including oncology and cell therapy applications. The company leverages proprietary drug development expertise in oRNA and LNP technology platforms.
Ronatherapeutics18 shared keywordsRona Therapeutics develops siRNA-based therapeutics using its GAIA platform to target metabolic and cardiovascular conditions including hypertriglyceridemia, obesity, ASCVD, and MASH. Its pipeline includes APOC3, INHBE, PCSK9-Lp(a), and angiotensinogen-targeting candidates for patients with cardiovascular and metabolic diseases.
Regeneron NASDAQ: REGN www.regeneron.com18 shared keywordsRegeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease. The company focuses on research and development driven by human biology, with a clinical trial pipeline addressing conditions like generalized myasthenia gravis.
Bioworld17 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Orogentx17 shared keywordsOrogen Therapeutics uses AI and machine learning to accelerate drug discovery, focusing on small molecule candidates for immuno-inflammatory diseases. The company combines computational chemistry, DNA-encoded library technology, and medicinal expertise to develop novel therapeutic medicines.
Aro Biotherapeutics16 shared keywordsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
Redona16 shared keywordsRedona Therapeutics is a drug discovery company co-founded by Harvard Medical School investigators focused on novel areas of biology. The company is led by experienced biotech executives with backgrounds in immunology, oncology, and translational medicine.
Companies competing with Rgenta Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Rgenta Therapeutics do?
- Rgenta develops orally available small molecule therapies that target RNA to address diseases previously considered undruggable, with programs in oncology (targeting proteins such as MYB in solid tumors and hematologic cancers) and central nervous system repeat expansion disorders like Huntington's disease. It operates in the RNA-targeted drug development space.
- Who founded Rgenta Therapeutics?
- Rgenta Therapeutics was founded by Travis Wager, Hualin Simon Xi, Zhiping Weng, Simon Xi in 2019.
- Who are Rgenta Therapeutics's investors?
- Rgenta Therapeutics's investors include Delos Capital, Vivo Capital, AMR Action Fund, Boehringer Ingelheim Venture Fund, Korea Investment Partners, Lilly Asia Ventures, Matrix Capital Management, Matrix Partners China.
- How much funding has Rgenta Therapeutics raised?
- Rgenta Therapeutics has disclosed $88.9M raised across 4 rounds.
- Where is Rgenta Therapeutics headquartered?
- Rgenta Therapeutics is headquartered in Cambridge, US.